<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848948</url>
  </required_header>
  <id_info>
    <org_study_id>2020-GI-01</org_study_id>
    <nct_id>NCT04848948</nct_id>
  </id_info>
  <brief_title>Impact of Calory Restriction and Biofeedback on Endocrine and Mental Health</brief_title>
  <official_title>Effects of Short-term Calory Restriction and Biofeedback on Anthropometric and Metabolic Parameters as Well as Biological and Psychological Stress Correlates in Healthy Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Backgroup/relevance: Overweight and obesity, defined by a respective body mass index of above&#xD;
      25 and 30 kg/m2, are getting increasingly common in all regions of the world. Obesity is&#xD;
      currently estimated to be present in more than 10% of the global population while overweight&#xD;
      roughly reached an estimate of 40% in 2016.&#xD;
&#xD;
      Overweight dramatically increases the risk for a wide range of disorders such as diabetes&#xD;
      mellitus and other metabolic and cardiovascular disorders subsumed under the term metabolic&#xD;
      syndrome, increasing the risk for life-threatening cardiovascular events such as myocardial&#xD;
      infarction and stroke. Similar to other chronic diseases such as mental health disorders,&#xD;
      prescribing medication was oftentimes insufficient and should be complemented by patient&#xD;
      empowerment to reach sufficient treatment adherence and control of lifestyle factors.&#xD;
      Thereby, overweight and obesity can easily be challenged by patients themselves without&#xD;
      pharmacological intervention.&#xD;
&#xD;
      Overweight may place central in the crossroad between metabolic and mental health for several&#xD;
      reasons. Excessive body fat is known to cause subclinical inflammation that was also&#xD;
      associated with many psychiatric disorders such as major depression. Similarly, the&#xD;
      hypothalamic-pituitary-adrenal axis relevant for stress response was shown to be dysregulated&#xD;
      in both metabolic and mental health disorders.&#xD;
&#xD;
      Study design: In this study, non-pharmacological interventions are applied in healthy women&#xD;
      with overweight or obesity and self-perceived psychological stress. Women staying at the &quot;la&#xD;
      pura&quot; women´s health resort (www.lapura.at/) are invited to partake in the study and receive&#xD;
      a short-term intervention of calory restriction. Thereby, either F.X. Mayr or&#xD;
      very-low-calory-diet (VLCD) will be applied, reducing calory intake to 700-800 kcal/die.&#xD;
      Following random assigment to four treatment arms, half of the women also receive a 7-session&#xD;
      clinical-psychological intervention consisting of biofeedback, individualized&#xD;
      psycho-education on stress prevention and mindlessness training.&#xD;
&#xD;
      Women are assessed at baseline and after two weeks of interventions for metabolic parameters&#xD;
      such as insulin functioning, anthropometric parameters such as body weight and body fat,&#xD;
      blood parameters such as sex hormones, fat metabolism and liver function, parameters of&#xD;
      neuroplasticity such as brain derived neurotrophic factor (BDNF), as well as psychological&#xD;
      and biological stress correlates and mental health symptom dimensions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">March 4, 2020</completion_date>
  <primary_completion_date type="Actual">March 4, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSS score</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>Perceived Stress Scale total score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BODI</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>buron-out-diagnostic-inventory scores, 4 summary items and 3 stress self-ratings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BSI</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>Brief Symptom Inventory, 9 dimensional subscores and global severity score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>waist-to-height ratio</measure>
    <time_frame>Baseline</time_frame>
    <description>Anthropometric parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Baseline</time_frame>
    <description>Glycated hemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>Baseline</time_frame>
    <description>Functional parameter for insulin resistance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matsuda Index</measure>
    <time_frame>Baseline</time_frame>
    <description>Functional parameter for insulin sensitivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body mass index</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>weight in relation to height</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRV</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>heart rate variability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body fat</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>measured by bioimpedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lean mass</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>measured by bioimpedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase angle</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>ratio of reactance versus electric resistance, measured by bioimpedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistin</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>Adipocines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>Adipocines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secretagogin</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>Adipocines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>Adipocines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDNF</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>brain derived neurotrophic factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estrogen</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>Sex hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>Sex hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteinizing hormone</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>Sex hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle-stimulating hormone</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>Sex hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>Lipid metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-density lipoprotein (HDL)</measure>
    <time_frame>Baseline, changes over two weeks</time_frame>
    <description>Lipid metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Bem sex role inventory, female, male, neutral scores</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Neuroendocrinology</condition>
  <condition>Mental Stress</condition>
  <condition>Psychological</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>F.X.Mayr &amp; Biofeedback</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two weeks of F.X. Mayr diet and biofeedback</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F.X.Mayr</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>two weeks of F.X. Mayr diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLCD &amp; Biofeedback</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two weeks of very low calorie diet and biofeedback</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLCD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>two weeks of very low calorie diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Calory Restriction (F.X. Mayr &amp; VLCD)</intervention_name>
    <description>VLCD restricts calory intake to 630 - 700 kcal per day (20% fat, 34% protein, 46% carbohydrates).&#xD;
F.X. Mayr diet similarly applies calorie restriction to 700 - 800 kcal per day and includes daily ingestion of isotonic magnesium sulfate solution.</description>
    <arm_group_label>F.X.Mayr</arm_group_label>
    <arm_group_label>F.X.Mayr &amp; Biofeedback</arm_group_label>
    <arm_group_label>VLCD</arm_group_label>
    <arm_group_label>VLCD &amp; Biofeedback</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Biofeedback</intervention_name>
    <description>Three sessions of biofeedback (50 minutes) over a time frame of 14 days, aimed at improving biological functions and especially heart-rate-variability under stress condition.</description>
    <arm_group_label>F.X.Mayr &amp; Biofeedback</arm_group_label>
    <arm_group_label>VLCD &amp; Biofeedback</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women willing to undergo two-weeks of calory restriction&#xD;
&#xD;
          -  at least 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  currently pregnant&#xD;
&#xD;
          -  any acute or a severe chronic illness&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VAMED Gender Insitute</name>
      <address>
        <city>Gars am Kamp</city>
        <state>Niederösterreich</state>
        <zip>3571</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Alexandra Kautzky-Willer</investigator_full_name>
    <investigator_title>Prof.Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

